The global eClinical solutions market value was US$ 6.9 billion in 2020. The global eClinical solutions market is forecast to reach US$ 23.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 13% during the forecast period from 2021-2030.
eClinical solutions manage clinical technologies and experts to enable clinical development to be accelerated. It includes electronic health records, consent forms, integrating technologies, electronic data capture, and clinical information management systems. In addition, it provides researchers with a solution to manage lengthy clinical research processes by providing an end-to-end approach.
Factors Influencing Market Growth
Impact Analysis of COVID-19
Due to the spread of the Coronavirus disease (COVID-19) globally, there has been a significant increase in the need for eClinical solutions to administer vaccines and manage patient data. As a result, many healthcare providers were using smart medical devices to improve data standardization, leading to market growth. Other growth-inducing factors include technological advancements and improvements made to cloud-based eClinical solutions.
Regional Insights
In 2020, North America held the largest revenue share for eClinical solutions market. With an increase in aging population and an increasing number of lifestyle-related diseases such as diabetes and cardiomyopathy, the market is likely to grow in the coming years. In addition, the presence of prominent players and sophisticated infrastructure is forecast to boost the growth of the market in the region.
Over the next few years, the market for eClinical solutions is likely to register a significant CAGR in the Asia Pacific region. The region's increasing prevalence of target chronic diseases like cancer, cardiovascular conditions, and infectious diseases drives demand for eClinical solutions. There have been increasingly more clinical trials outsourced to countries like China, India, Korea, and Japan because of their large populations and low costs. As a result, eClinical solutions have gained traction in these regions. Government funding related to research and drug discovery is driving the market growth in the APAC, which is estimated to enhance its expansion over the forecast period.
Leading Competitors
The leading prominent companies profiled in the global eClinical solutions market are:
Scope of the Report
The global eClinical solutions market segmentation focuses on Product, Delivery Mode, Development Phase, End-Use, and Region.
Segmentation based on Product
Segmentation based on Delivery Mode
Segmentation based on Development Phase
Segmentation based on End-Use
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL E-CLINICAL SOLUTIONS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL E-CLINICAL SOLUTIONS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL E-CLINICAL SOLUTIONS MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 CLINICAL ANALYTICS PLATFORMS
5.3 CLINICAL DATA INTEGRATION PLATFORMS
5.4 CLINICAL TRIAL MANAGEMENT SYSTEMS (CTMS)
5.5 ELECTRONIC CLINICAL OUTCOME ASSESSMENT
5.6 ELECTRONIC DATA CAPTURE (EDC) AND CLINICAL DATA MANAGEMENT SYSTEMS (CDMS)
5.7 ELECTRONIC TRIAL MASTER FILE (ETMF)
5.8 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM)
5.9 SAFETY SOLUTIONS
6 GLOBAL E-CLINICAL SOLUTIONS MARKET, BY DELIVERY MODE
6.1 OVERVIEW
6.2 CLOUD-BASED
6.3 LICENSED ENTERPRISE (ON-PREMISE)
6.4 WEB-HOSTED (ON-DEMAND)
7 GLOBAL E-CLINICAL SOLUTIONS MARKET, BY DEVELOPMENT PHASE
7.1 OVERVIEW
7.2 PHASE I
7.3 PHASE II
7.4 PHASE III
7.5 PHASE IV
8 GLOBAL E-CLINICAL SOLUTIONS MARKET, BY END-USE
8.1 OVERVIEW
8.2 ACADEMIC INSTITUTES
8.3 CONTRACT RESEARCH ORGANIZATION (CROS)
8.4 HOSPITALS/HEALTHCARE PROVIDERS
8.5 MEDICAL DEVICE MANUFACTURERS
8.6 PHARMA & BIOTECH ORGANIZATIONS
9 GLOBAL E-CLINICAL SOLUTIONS MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3. 1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL E-CLINICAL SOLUTIONS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
11 COMPANY PROFILES
11.1 ANJU LIFE SCIENCES SOFTWARE
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.2 BIOCLINICA
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.3 CRF HEALTH
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.4 DASSAULT SYSTEMES
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.5 DATATRAK INTERNATIONAL, INC.
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.6 E-CLINICALWORKS
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.7 ERT CLINICAL
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.8. IBM
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.9 ORACLE
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.10 PAREXEL INTERNATIONAL CORPORATION
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
The global eClinical solutions market revenue was around US$ 7.65 billion in 2022 and is estimated to reach US$ 21.5 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.2% during the forecast period from 2023 to 2031.
eClinical solutions are software-based solutions utilized for effective management and data-generated integration during clinical trials. It is commonly utilized in clinical trials for drug development processes in all phases and for medical device developments. In eClinical solutions, the software is utilized for patient registration, clinical research outcomes generation, monitoring of negative effects, and complaint submission.
Market Driving Factors
Increasing adoption of novel software solutions in clinical research is expected to drive the market. Patient recruitment and retention are significant operational challenges for most researchers during clinical research studies. In addition, the lack of real-time access to research data and manual data generation for protocol matrices often outcomes in extended timelines and raises research expenditures associated with clinical trials. Furthermore, this may affect all phases, especially research planning, data management, reporting and regulatory submission, and data analysis, resulting in delayed market entry of successful drug candidates. As a result, researchers surging prefer innovative eClinical solutions that provide enhanced efficiency of clinical trials, improve site performance, and have higher price efficiency than traditional methodologies.
Surging outsourcing of clinical trial processes to Contract Research Organizations (CROs) is expected to create opportunities in the market. This is mainly due to the pharmaceutical and biotechnology product manufacturing companies being the prior end users of clinical trial software and products. However, many CROs and research-based companies are providing specific research services to different end users owing to the surging availability of public-private research funding and supporting private R&D infrastructure across major markets. As a result, pharmaceutical and biotechnology companies are increasingly outsourcing less significant clinical research activities to these CROs and research companies.
A high capital price is estimated to limit the market expansion.
Regional Analysis
North America dominated the market in terms of the largest revenue and is estimated to maintain its dominance. This can be attributed to the surged target population, coupled with the raised prevalence of lifestyle-associated diseases such as cardiac and diabetes disorders. Additionally, the launch of new products by eClinical solution agents and a surge in government grants have also boosted the market in the region.
Asia Pacific is estimated to dominate the market in terms of the largest shares. This is mainly due to the high unmet medical requirements and increasing prevalence of target chronic disorders such as cardiovascular conditions, cancer, and infectious diseases are increasing the demand for software solutions in the region. Furthermore, a surging number of trials are outsourced to nations such as India, China, Japan, and Korea, due to a large patient population and low price. Thus, this factor is estimated to boost the adoption of eClinical solutions in these countries.
Segmentation Insights
Clinical Trial Phase Insight
The phase I segment is estimated to dominate the market in terms of the highest shares. This is majorly owing to the high significance of these systems in predicting future results and eliminating drug candidates possessing the smallest probability of success.
End User Insight
The contract research organization segment dominated the market in terms of the growth rate and is expected to maintain its dominance. This can be primarily attributed to the inclination of pharmaceutical companies to lower overall expenditure enhanced clinical trials and streamlined research workload.
The pharmaceutical and biopharmaceutical companies segment is estimated to dominate the market in terms of significant growth. This is mainly owing to the surging adoption of eClinical solutions by researchers that offer enhanced clinical trials and simplified research workload. In addition, such software solutions allow biotechnology and pharmaceutical companies to determine procedural blockages related to clinical trials. This, in turn, is propelling the demand for eClinical solutions among researchers in pharmaceutical and biotechnology companies for clinical research programs.
Product Insight
The electronic data capture and clinical data management systems segment dominated the market in terms of revenue and is predicted to maintain its dominance. This can be majorly attributed to the quality of details captured, streamlines data collection procedures, and provides effective data analysis.
Prominent Companies
Segmentation Outline
The global eClinical solutions market segmentation focuses on the Delivery Mode, Clinical Trial Phase, Product, End User, and Region.
By Delivery Mode
By Clinical Trial Phase
By Product
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL eCLINICAL SOLUTIONS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: eCLINICAL SOLUTIONS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL eCLINICAL SOLUTIONS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL eCLINICAL SOLUTIONS MARKET, BY DELIVERY MODE
5.1 OVERVIEW
5.2 WEB-HOSTED
5.3 ON-PREMISE
5.4 CLOUD-BASED
6 GLOBAL eCLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
6.1 OVERVIEW
6.2 PHASE I
6.3 PHASE II
6.4 PHASE III
6.5 PHASE IV
7 GLOBAL eCLINICAL SOLUTIONS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 CLINICAL TRIAL MANAGEMENT SYSTEMS
7.3 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT
7.4 ELECTRONIC CLINICAL OUTCOME ASSESSMENT
7.5 ELECTRONIC TRAIL MASTER FILES
7.6 ELECTRONIC DATA CAPTURE AND CLINICAL DATA MANAGEMENT SYSTEMS
7.7 OTHERS
8 GLOBAL eCLINICAL SOLUTIONS MARKET, BY END USER
8.1 OVERVIEW
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
8.3 CONTRACT RESEARCH ORGANIZATIONS
8.4 OTHERS
9 GLOBAL eCLINICAL SOLUTIONS MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL eCLINICAL SOLUTIONS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 BUSINESS SYSTEMS INTEGRATION AG
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 PAREXEL INTERNATIONAL CORPORATION
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 ORACLE CORPORATION
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 MEDRIO INC.
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 ANJU SOFTWARE INC.
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 IBM WATSON HEALTH
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 SIGNANT HEALTH
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8 ADVARRA INC
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 CLARIO
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 ECLINICAL SOLUTIONS INC.
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 MEDNET SOLUTIONS
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.12 VEEVA SYSTEMS
11.12.1 OVERVIEW
11.12.2 FINANCIAL PERFORMANCE
11.12.3 PRODUCT OUTLOOK
11.12.4 KEY DEVELOPMENTS
11.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.13 CASTOR EDC
11.13.1 OVERVIEW
11.13.2 FINANCIAL PERFORMANCE
11.13.3 PRODUCT OUTLOOK
11.13.4 KEY DEVELOPMENTS
11.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.14 DASSAULT SYSTEMES
11.14.1 OVERVIEW
11.14.2 FINANCIAL PERFORMANCE
11.14.3 PRODUCT OUTLOOK
11.14.4 KEY DEVELOPMENTS
11.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.15 MAXISIT INC
11.15.1 OVERVIEW
11.15.2 FINANCIAL PERFORMANCE
11.15.3 PRODUCT OUTLOOK
11.15.4 KEY DEVELOPMENTS
11.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.16 SAAMA TECHNOLOGIES INC
11.16.1 OVERVIEW
11.16.2 FINANCIAL PERFORMANCE
11.16.3 PRODUCT OUTLOOK
11.16.4 KEY DEVELOPMENTS
11.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.17 DATATRAK INTERNATIONAL INC.
11.17.1 OVERVIEW
11.17.2 FINANCIAL PERFORMANCE
11.17.3 PRODUCT OUTLOOK
11.17.4 KEY DEVELOPMENTS
11.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved